Potential Upside for Sarepta (SRPT) as BioMarin (BMRN) Pulls Kyndrisa Marketing App in Europe - Oppenheimer
Tweet Send to a Friend
Oppenheimer affirms BioMarin Pharma (Nasdaq: BMRN) with a Perform rating and $99 price target after the company announced that it ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
